Document text
Principal Investigator: DENNIS J. HARTIGAN-O'CONNOR
Organization: TENDEL THERAPIES INC.
Fiscal Year: 2024
Award: $300,083
Funding agency: National Institute of Mental Health
This project will test the ability of T follicular helper (Tfh) cell-targeting “genetic adjuvants” to improve
immunogenicity of an advanced HIV envelope (Env) trimer. Eliciting neutralizing antibodies (nAb) against
HIV will likely be required to create effective therapeutic vaccines that attenuate HIV disease progression,
reduce HIV infectiousness, or even effect sustained remission in the absence of daily antiretroviral drug
therapy. However, eliciting such antibodies is a challenge that can be frustrated at multiple steps in B-cell
development, particularly in HIV-infected people. Of greatest relevance to this application, low-affinity germline
B cells reactive to neutralizing epitopes may not successfully compete with cells binding non-neutralizing
epitopes for antigen, or the amount of antigen acquired may be insufficient to stimulate Tfh cells to provide the
required help.
Tendel Therapies Inc. developed B-cell adjuvant technology that augments Tfh cells and is designed for use
with vectored vaccines. Our preliminary data show that the adjuvant acts on both Tfh and B cells to promote
uniquely intense and durable antibody responses. We propose to use these adjuvants in combination with two
promising B-cell immunogens to reliably elicit tier-2 neutralizing antibodies in macaques: (i) an advanced
BG505 SOSIP-like trimer designed to promote focused responses to nAb targets and minimize reactivity of
non-neutralizing Env epitopes such as the V3 loop or non-neutralizing CD4 binding site sub-regions, and (ii)
bacteriophage VLPs displaying the HIV fusion peptide (FP) in highly multimeric form.
We hypothesize that novel Tfh-targeting adjuvants promote broader nAb responses to an advanced HIV Env
immunogen via mechanisms including democratic naïve B-cell recruitment and stimulation of Tfh responses.
Aim 1. Assess the intensity and durability of nAb, Tfh, and germinal center B-cell responses to an
advanced HIV envelope trimer, delivered with or without Tendel adjuvants, as mRNA in lipid
nanoparticles. The goals are (i) to test if Tendel adjuvants have similar potency for augmentation of antibody
responses to mRNA-vectored vaccination against native-like HIV Env trimers, as previously shown for
augmentation of responses against the SARS-CoV-2 receptor binding domain; and (ii) to select one regimen
for evaluation in Aim 2 subsequent to fusion-peptide priming.
Aim 2. Evaluate the effect of priming immunization with the HIV Env fusion peptide, FP8, on
neutralization breadth achieved by Tendel adjuvants and HIV Env native-like trimers. This priming
regimen is intended to provide an additional epitopic focus for nAb responses. Due to the combination of anti-
FP nAbs with other nAbs provided by trimer immunization, the FP8-primed regimen should result in nAb
responses of increased breadth and perhaps higher titer.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><AIDS Virus><Ab response><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adjuvant><Affinity><Amino Acids><Anti-Retroviral Agents><Antibodies><Antibody Formation><Antibody Production><Antibody Response><Antigenic Determinants><Antigens><Attenuated Vaccines><B blood cells><B cell><B cells><B-Cell Development><B-Cells><B-Lymphocytes><B-cell><Bacteriophages><Binding><Binding Determinants><Binding Sites><COVID-19 vaccine><COVID-19 virus><COVID19 virus><Cell Body><Cells><Clinical Evaluation><Clinical Testing><Clinical Trials><CoV-2><CoV2><Combining Site><Data><Development><Disease Progression><Disease remission><Drug Therapy><Epitopes><Evaluation><Frequencies><Frustration><Funding><Genetic><Germ Lines><Germinal Center><Goals><Government><HIV><HIV envelope><HIV envelope protein><HIV vaccine><HIV-1><HIV-I><HIV/AIDS Vaccines><HIV1><Hand><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Immune system><Immunization><Immunoactivators><Immunoadjuvants><Immunologic Adjuvants><Immunopotentiators><Immunostimulants><Inducer Cells><Inducer T-Lymphocytes><Infection><LAV-HTLV-III><Left><Live-attenuated Vaccine><Lymphadenopathy-Associated Virus><Macaca><Macaque><Messenger RNA><Modern Man><Molecular Interaction><N-terminal><NH2-terminal><Peptides><Persons><Phages><Pharmacotherapy><Polymers><Preventative Immunization><Preventative vaccination><Preventive Immunization><Preventive vaccination><Primates><Primates Mammals><Prophylactic immunization><Prophylactic vaccination><Reactive Site><Regimen><Remission><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 vaccine><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Structure of germinal center of lymph node><Surface><Technology><Testing><V3 Loop><V3 Loop of HIV-1><VAC-TX><Vaccination><Vaccine Therapy><Vaccines><Virus><Virus-HIV><Work><Wuhan coronavirus><aminoacid><anti-retroviral><antibody biosynthesis><bacterial virus><clinical test><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19 vaccine><coronavirus disease-19 virus><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><drug treatment><experiment><experimental research><experimental study><experiments><hCoV19><hands><human immunodeficiency virus vaccine><immunogen><immunogenicity><immunoglobulin biosynthesis><improved><lipid based nanoparticle><lipid nanoparticle><live vaccine><live vaccines><mRNA><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><neutralizing antibody><non-human primate><nonhuman primate><novel><plasmid vaccine><polymer><polymeric><receptor binding><receptor bound><recruit><research clinical testing><response><therapeutic vaccination><therapeutically effective><vaccination protocol><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine development><vaccine for novel coronavirus><vaccine protocol><vaccines preventing COVID><vaccines to prevent COVID><vector><vector vaccine>